ESC 365 - Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin

ESC Premium Access

Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin

Session: New developments in anti thrombotic drug therapy

Topic: Anticoagulants

Speaker: Assistant Professor C. Koh (Singapore, SG)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Assistant Professor Cho Yeow Koh

National University of Singapore, Singapore (Singapore)

0 follower

3 more presentations in this session

State of the Art - Novel targets in anti thrombotic drug development

Speaker: Professor B. Rocca (Casamassima, IT)

Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients

Speaker: Professor R. Storey (Sheffield, GB)

Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452

Speaker: Professor L. Jennings (Memphis, US)

Access the full session

New developments in anti thrombotic drug therapy

Speakers: Assistant Professor C. Koh, Professor B. Rocca, Professor R. Storey, Professor L. Jennings

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources